

It's more than just science;  
it's a matter of life.

Neurologix, Inc. (NRGX) is a development-stage company which is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system, primarily utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease, epilepsy and Huntington's disease. Neurologix's core technology, "NLX," is currently being tested in a Company-sponsored Phase I human clinical trial to treat Parkinson's disease.

## Investment Highlights

- **Progress.** Unique gene therapy treatment for Parkinson's disease achieving success in Phase I clinical trials. Possibility of accelerating to pivotal trials in the next 24 months. Achieving outstanding results with no significant adverse events related to the gene therapy.
- **Gene Therapy – Better Than Ever.** Once out of favor, gene therapy is proving its resilience. Recent scientific breakthroughs and landmark trials have restored confidence in this successful approach. Recent Business Week article entitled "Gene Therapy is Respectable Again" underscores that point.
- **Multiple Growth Opportunities.** This same gene therapy has potential for successfully treating epilepsy, Huntington's disease and depression. Also, there are possible applications for a number of other conditions.
- **Strong Partner.** Medtronic (NYSE:MDT), one of the world's best-known providers and distributors of medical devices, is both a partner and investor. Medtronic has made two substantial equity investments in Neurologix and is currently developing the catheter system that will be used to infuse Neurologix therapies into the brain.
- **Market Potential.** According to the National Parkinson Foundation, there are approximately 1.5 million Parkinson's disease patients in the United States, with 60,000 new cases diagnosed each year. Accessing just 100,000 of these patients creates a \$2 billion annual market opportunity.
- **Licenses and Patents.** Neurologix's proprietary gene therapies are a gateway to potential treatments for an array of central nervous system disorders. These therapies may be used to also treat pain, depression, drug addiction and alcoholism.
- **Successful Recent Financing.** The Company recently completed a private placement of \$12 million of Series C Convertible Preferred Stock. The purchasers in the transaction were the General Electric Pension Trust, the DaimlerChrysler Corporation Master Retirement Trust and certain funds managed by ProMed Management, Inc.
- **Founders.** The scientific founders of Neurologix include Matthew J. During, M.D., D.Sc., an internationally recognized leader and pioneer in gene therapy, and Michael G. Kaplitt, M.D., Ph.D., an expert and innovator in gene therapy who was among the first scientists to publish on the use of viruses for direct gene delivery in the living brain. Also, heading up the Medical Advisory Board is 2000 Nobel Laureate Dr. Paul Greengard.
- **Experienced Management.** Company officers include:
  - ~ **John E. Mordock**, *President and Chief Executive Officer*, formerly president of The Surgical & Medical Services Group of Teleflex, Inc., a NYSE listed company, and a founder and the president of Cabot Medical, Inc., a NASDAQ listed company.
  - ~ **Martin J. Kaplitt, M.D.**, *Chairman*, formerly Chief of the Division of Cardiac Surgery at North Shore University Hospital in Manhasset, New York.
  - ~ **Marc Panoff**, *Chief Financial Officer and Treasurer*, formerly Chief Financial Officer of Nephros, Inc., as well as Corporate Controller of Medicis Pharmaceutical Corporation.
  - ~ **Christine V. Sapan, Ph.D.**, *Executive Vice President and Chief Development Officer*, formerly Vice President, Project Management, Nabi Pharmaceuticals, a biopharmaceutical company focusing on serious unmet medical needs, including infectious disease.

## Contact:

John E. Mordock  
Chief Executive Officer  
(201) 592-6451

## Company Information:

OTCBB Symbol: NRGX  
Stock Price (07/20/06): \$1.33  
Shares Outstanding: 26.5 million  
Market Capitalization: \$35 million

## Cautionary Statement Regarding Forward-looking Statements

*This fact sheet includes certain statements of the Company that may constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and which are made pursuant to the Private Securities Litigation Reform Act of 1995. These forward-looking statements and other information relating to the Company are based upon the beliefs of management and assumptions made by and information currently available to the Company. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements.*

*Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information regarding factors that could cause results to differ materially from management's expectations is found in the section entitled "Risk Factors" in the Company's 2005 Annual Report on Form 10-KSB. Although the Company believes these assumptions are reasonable, no assurance can be given that they will prove correct. Accordingly, you should not rely upon forward-looking statements as a prediction of actual results. Further, the Company undertakes no obligation to update forward-looking statements after the date they are made or to conform the statements to actual results or changes in the Company's expectations.*